Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
This study has been completed.
Study NCT00661544 Information provided by M.D. Anderson Cancer Center
First Received: April 15, 2008 Last Updated: May 21, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple Myeloma
Stem Cell Transplantation
Additional conditions recognized in this trial
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
Arsenic Trioxide
Melphalan
Ascorbic Acid
Additional drug interventions recognized in this trial
Vitamins
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antioxidants
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Cell Therapeutics
Back to top of Main Content
